Should You Buy Exelixis Stock For Its Cash?
Today’s big story: Could Anthropic Stock Fall 25%?
Exelixis (EXEL) produced free cash flow equal to 6.8% of its market value over the past twelve months. The median S&P 500 company produced 4.3%. A cash yield that high can mean a business on sale or one the market expects to shrink. So what does that cash give you as an owner, and how is it made?

What Exelixis’s Cash Yield Gives You As An Owner
Shareholders own a slice of the free cash a business produces, whether or not it is paid out. Cash kept inside the company still belongs to its owners. When the market recognizes that cash, the stock price tends to follow, more so when the cash is growing.
Exelixis produced $1.14 billion of free cash flow over the twelve months to September 2026. That was 45.8% of its revenue. Its gross margin was 96.3% over those twelve months, so making its drugs costs little against what they sell for. Capital spending took just 2.4% of the cash its operations brought in. Over the same twelve months, Exelixis spent $1.26 billion buying back its own shares, more than its free cash flow.
Exelixis kept 45.8% of its revenue as cash over the past twelve months, after its costs and investment. That cash rests mostly on one drug, so a big stake in this one stock could mean a steep fall to sit through. Bring your hardest question to a free 30-minute call with our partner advisory firm, by phone or video. No obligation. Book a free call.
How Steady Has Exelixis’s Cash Been?
Exelixis’s free cash flow has grown in each of the past two years. The figure rose from $405 million in the twelve months to September 2024 to $744 million a year later. It stayed positive in all 13 twelve-month periods that ended between September 2023 and September 2026.
The business grew alongside the cash. Revenue reached $2.5 billion over the latest twelve months, up 9.1% from a year earlier. The operating margin, the share of revenue left as operating profit, widened to 40.2% from 29.2% two years before.
Debt is not a strain either. Exelixis held $892 million of cash and short-term investments at the end of September 2026, against $162 million of debt. On these figures, Exelixis looks more like a business on sale than one in decline.
How Much Of Exelixis’s Revenue Comes From One Drug?
CABOMETYX, its main cancer drug, brought in $2.11 billion of Exelixis’s $2.32 billion revenue in fiscal 2025. That is where a buyer’s doubt likely sits, since so much of the cash depends on one product.
Growth has also cooled. Twelve-month revenue growth slowed from 17.3% in the period to September 2024 to 9.9% a year later, and eased again in the latest year. In August 2026, management cut its revenue guidance. It tied the cut to revenue growth from the drug’s use in neuroendocrine tumors (NET), which it saw as temporary. In October, Exelixis kept its fiscal 2026 revenue guide at $2.50 billion to $2.55 billion.
Management sees a newer drug, zanzalintinib, as its next source of growth. The FDA’s decision date on its application is March 3, 2027. For now, the stock price appears to assume slower growth. Exelixis trades at 19.0 times earnings against 21.5 for the S&P 500.
What Will Show Whether Exelixis’s Cash Keeps Growing?
The open question is whether the cash keeps growing while Exelixis relies on one drug. Management’s fiscal 2026 guide points to more revenue than in fiscal 2025, though a guide is a forecast, not a result. Exelixis’s debt does not look like a worry for now, since it holds more cash than it owes.
Exelixis is expected to report its fiscal 2026 results in February 2027. That report will show the full year’s free cash flow, arriving a month before the FDA’s decision date on zanzalintinib.
Exelixis shows how much cash one strong drug can produce, and how exposed an owner is to that one drug. Spreading your money across many companies is one way to collect steady cash with smaller drops when one of them stumbles.
More Income. Smaller Drops.
Is your portfolio paying you enough? The Trefis Income Solution holds 50 dividend stocks yielding about 3x the S&P 500, each with at least 10 straight years of dividends. It lost less than the S&P 500 in all 9 big selloffs since 2018. Why not choose a better approach?
Spot an error or want more like this? Tell us in 10 seconds.